Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades

By: via Benzinga
Lipocine Inc (NASDAQ: LPCN), a pharma company focusing on men's and women's health, announced Wednesday the FDA's Bone, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.